BLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
ADUHELM (aducanumab-avwa) by Biogen. Approved for alzheimer's disease. First approved in 2021.
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (1)
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
Started Nov 2021
29 enrolled
Alzheimers Disease
Company
Worked on ADUHELM at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.